Thursday, June 24, 2021

Real-world remdesivir data add to body of evidence for Gilead Sciences Covid-19 drug

  The Gilead Sciences drug remdesivir became the first FDA-approved treatment for Covid-19 based on data from three Phase 3 clinical trials enrolling a little more than 2,000 patients. The company now has new real-world data from 98,654 hospitalized patients that lend additional support for use of the drug. According to the studies, treatment...

Survey: Most health organizations hit by ransomware had their data encrypted

In 2020, 34% of healthcare organizations worldwide were hit by a ransomware attack, of which 65% said the cybercriminals succeeded in encrypting their data in the most significant attack, according to a new report. Released by cybersecurity solutions provider Sophos, the report includes the results of a survey that polled 5,400 IT decision-makers across...

Amazon’s cloud services business launches digital health accelerator

Amazon’s cloud services business is launching a new healthcare accelerator for startups. Called the AWS Healthcare Accelerator, the four-week program will pick 10 startups using cloud technology to respond to challenges in healthcare. “The program is tailored to accelerate growth in the cloud, with a focus on solutions like remote patient monitoring, voice technology,...

Arrowhead Pharma hands Horizon rights to gene-silencing gout drug for $40M

gout
  An Arrowhead Pharmaceuticals “gene-silencing” drug that the biotech has been quietly researching as a gout treatment will continue its development under a partnership with Horizon Therapeutics. Horizon has agreed to pay $40 million up front for global rights to the drug, ARO-XDH. According to deal terms announced Monday, Pasadena, California-based Arrowhead will handle...

Should governments institute pandemic lockdowns? Depends on the Data

Road sign indicating essential travel only due to the Covid-19 lockdown Although it continues to run strong in some countries, the Covid pandemic is in retreat in many parts of the world, including much of the US. With that, it will likely be some time before the world returns to pre-2020 conditions. But even...

What have we learned about accelerating drug development from Covid-19?

In response to Covid-19, the global drug development community has moved faster and further than ever before. But what have we learned from meeting this emergency? Players throughout the ecosystem, from drug developers to regulators, are considering how we can apply real-world lessons to benefit patients in the future. While drug developers succeeded in...

Q&A: Cleveland Clinic Innovations’ new head has his eyes trained on the future

Dr. Geoff Vince
An engineer by training, Dr. Geoff Vince plans to leverage his process-driven traits in his new role as executive director of Cleveland Clinic Innovations, the health system’s commercialization arm. Named to the role at the end of May, following a decade as chair of the biomedical engineering department, Vince is now charged with aligning...

Former athenahealth CEO reemerges with new health IT startup

Jonathan Bush, chairman and CEO of athenahealth
 Jonathan Bush, the controversial former CEO of athenahealth, is re-emerging with a new health IT venture.  Bush was ousted from athenahealth three years ago, while the company faced a takeover bid by activist investor Elliott Management. During that time, old court records came to light showing domestic violence allegations from his ex-wife. He apologized,...

INVEST Pitch Perfect winner spotlight: Systems Oncology’s AI tech yields trove of cancer drugs

  The biopharmaceutical industry continues to churn out new cancer medicines, and some of them work for awhile. Over time, cancers can develop resistance to old drugs and new ones, winnowing away the treatment options for patients. Spryo Mousses, CEO and co-founder of Systems Oncology, said his startup grew out of the desire to...

Lyell, Verve IPOs raise a combined $692M as both biotechs steer toward clinical trials

  At one time, preclinical biotechs had a hard time pulling off IPOs. Investors wanted to see early data from tests in humans to reduce their financial risk. But Lyell Immunopharma and Verve Therapeutics aren’t the typical preclinical biotech companies. Each led by a prominent physician, they’re developing novel genetic approaches to treat cancer...
0FansLike
0FollowersFollow
- Advertisement -

Must Read